The FDA is currently reviewing Moderna's flu shot, a development that could have significant implications for public health.
In a strategic move, Johnson & Johnson has opted not to pursue opportunities in the rapidly growing obesity market.
Instead, the company has reaffirmed its commitment to focusing on cancer-related diseases, aligning its resources with its long-term goals.